The present invention relates to a composition comprising ethyl vanillin or a pharmaceutically acceptable salt thereof as an effective ingredient for preventing or treating muscle disease or for improving a muscle function. Having the capability of upregulating the expression of a protein associated with muscle protein synthesis and muscle mass increase in myocytes and downregulating at an mRNA level the expression of an enzyme involved in muscle protein degradation, ethyl vanillin can exhibit effects of muscle differentiation, muscle regeneration, and muscle strengthening through an increase in muscle mass against muscle diseases attributed to muscle function decrease, muscle consumption, or muscle degradation and can suppress sarcopenia. Thus, ethyl vanillin can be used for preventing or treating muscle diseases or for promoting muscle differentiation, muscle regeneration and muscle strengthening, muscle mass increase, or muscle generation or for improving muscle function.

The present invention relates to a composition comprising ethyl vanillin or a pharmaceutically acceptable salt thereof as an effective ingredient for preventing or treating muscle disease or for improving a muscle function. Having the capability of upregulating the expression of a protein associated with muscle protein synthesis and muscle mass increase in myocytes and downregulating at an mRNA level the expression of an enzyme involved in muscle protein degradation, ethyl vanillin can exhibit effects of muscle differentiation, muscle regeneration, and muscle strengthening through an increase in muscle mass against muscle diseases attributed to muscle function decrease, muscle consumption, or muscle degradation and can suppress sarcopenia. Thus, ethyl vanillin can be used for preventing or treating muscle diseases or for promoting muscle differentiation, muscle regeneration and muscle strengthening, muscle mass increase, or muscle generation or for improving muscle function.

The invention relates to a process for the manufacture of a perchlorate depleted milk based on nanofiltration of dairy raw materials. The invention further relates to methods for the preparation of an infant formula base using said perchlorate depleted milk. The invention also envisages a perchlorate depleted retentate fraction used to produce a perchlorate depleted milk and infant formula, an assortment comprising said formula and a system for the manufacture of an infant formula comprising a nanofiltration module.

The invention relates to a process for the manufacture of a perchlorate depleted milk based on nanofiltration of dairy raw materials. The invention further relates to methods for the preparation of an infant formula base using said perchlorate depleted milk. The invention also envisages a perchlorate depleted retentate fraction used to produce a perchlorate depleted milk and infant formula, an assortment comprising said formula and a system for the manufacture of an infant formula comprising a nanofiltration module.

Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

Choline alfoscerate is a drug used to improve cerebrovascular diseases and brain metabolism. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with muscle cramps, it can significantly reduce pain and the occurrence of muscle cramps. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing muscle cramps and a health functional food composition for improving muscle cramps and may also be used for a method for treating muscle cramps by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating muscle cramps.

Choline alfoscerate is a drug used to improve cerebrovascular diseases and brain metabolism. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with muscle cramps, it can significantly reduce pain and the occurrence of muscle cramps. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing muscle cramps and a health functional food composition for improving muscle cramps and may also be used for a method for treating muscle cramps by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating muscle cramps.

The present disclosure relates to a method for preventing, alleviating, improving or treating female hormone regulation disorder or symptoms, which contains a green tea extract with contents of ingredients changed. Specifically, the method according to an aspect of the present disclosure includes a step of administering an effective amount of a green tea extract, which contains (−)-gallocatechin gallate (GCG) and (−)-epigallocatechin gallate (EGCG) at specific contents, to a subject in need thereof, and may exhibit an effect of preventing, alleviating, improving or treating female hormone regulation disorder or symptoms.

The present disclosure relates to a method for preventing, alleviating, improving or treating female hormone regulation disorder or symptoms, which contains a green tea extract with contents of ingredients changed. Specifically, the method according to an aspect of the present disclosure includes a step of administering an effective amount of a green tea extract, which contains (−)-gallocatechin gallate (GCG) and (−)-epigallocatechin gallate (EGCG) at specific contents, to a subject in need thereof, and may exhibit an effect of preventing, alleviating, improving or treating female hormone regulation disorder or symptoms.